Advertisement

Cell Therapy pp 281-295 | Cite as

Cell Therapy: Approaching a Partnership with Pharma

  • Vincent LingEmail author
Chapter
Part of the Molecular and Translational Medicine book series (MOLEMED)

Abstract

The translation of cell biology science to an applied medical therapy holds great allure for forward-thinkers in the medical industry. As with any other futuristic technologies, exotic therapies need to be more medically effective than current treatments, sufficiently robust to be scaled reproducibly, and economically viable as a commercial product. This chapter is a primer on what an academic cell biologist/inventor may expect when seeking funding from a typical pharmaceutical company to develop a cell therapy.

Keywords

Cell encapsulation Regenerative medicine Cell therapy MSC iPS ARPE-19 Islet CAR-T Business development Biotechnology Innovation Start-up 

References

  1. 1.
    Haucap J, Stiebale J. Research: innovation suffers when drug companies merge. Harv Bus Rev (online). 2016. Accessed 19 Oct 2016.
  2. 2.
    Cyran R. Change is in the air for pharmaceutical mergers. New York Times (online). 2016. Accessed 19 Oct 2016.
  3. 3.
    Smith AG. Price gouging and the dangerous new breed of pharma company. Harv Bus Rev (online). 2016. Accessed 19 Oct 2016.
  4. 4.
    Thomas H. GSK’s sturdy strategy leaves investors waiting. Wall Street J (online). 2015. Accessed 19 Oct 2016.
  5. 5.
    DiMasi J, Grabnowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33. doi: 10.1016/j.jhealeco.2016.01.012.CrossRefPubMedGoogle Scholar
  6. 6.
    Bajak A. Will embryonic stem cells cure anything? MIT Technol Rev (online). 2016. Accessed 19 Oct 2016.
  7. 7.
    Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25(5):829–48. doi: 10.3727/096368915X689622.CrossRefPubMedGoogle Scholar
  8. 8.
    Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S, ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388(10051):1281–90. doi: 10.1016/S0140-6736(16)31203-X.CrossRefPubMedGoogle Scholar
  9. 9.
    Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13(6):370–83. doi: 10.1038/nrclinonc.2016.36.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011. doi: 10.1038/mto.2016.11.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wang X, Rivière I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015. doi: 10.1038/mto.2016.15.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Lathuilière A, Mach N, Schneider BL. Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system. Int J Mol Sci. 2015;16(5):10578–600. doi: 10.3390/ijms160510578.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kauper K, McGovern C, Sherman S, Heatherton P, Rapoza R, Stabila P, Dean B, Lee A, Borges S, Bouchard B, Tao W. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Ophthalmol Vis Sci. 2012;53(12):7484–91. doi: 10.1167/iovs.12-9970.CrossRefPubMedGoogle Scholar
  14. 14.
    Ling V, Nystuen A, Elliott S, Orecchio L, Dean B, Kauper K, Tao W. Generation of Combination PDGF/VEGF-antagonist ECT devices. Invest Ophthalmol Vis Sci. 2013;54:3290.Google Scholar
  15. 15.
    Wahlberg LU, Lind G, Almqvist PM, Kusk P, Tornøe J, Juliusson B, Söderman M, Selldén E, Seiger Å, Eriksdotter-Jönhagen M, Linderoth B. Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer’s disease: a technology platform for restorative neurosurgery. J Neurosurg. 2012;117(2):340–7. doi: 10.3171/2012.2.JNS11714.CrossRefPubMedGoogle Scholar
  16. 16.
    Lathuilière A, Mach N, Schneider BL. Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system. Int J Mol Sci. 2015;16(5):10578–600. doi: 10.3390/ijms160510578. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.BioEntrepreneurWalpoleUSA

Personalised recommendations